Tags

Type your tag names separated by a space and hit enter

Biomarkers in preclinical Alzheimer's disease.
Curr Opin Investig Drugs 2006; 7(7):600-7CO

Abstract

With the recent advances in the treatment of Alzheimer's disease (AD) over the last decade, the focus has increasingly shifted to accurate detection of the earliest phase of illness. The intermediate state between normal aging and established AD is commonly known as mild cognitive impairment (MCI). Not all patients with MCI progress to AD and hence there is a need to reliably predict which patients with MCI will progress. The current inability of clinical criteria to accurately identify this at-risk group is fuelling the emerging interest in biomarkers to potentially supplement or replace clinical approaches. Biomarkers have the potential to clearly reflect the progressive deterioration that is present even in the earliest stages of AD--a useful feature for demonstrating the effectiveness or otherwise of a particular dementia drug. This paper will review the evidence regarding the use of cerebrospinal fluid, neuroimaging and blood biomarkers, as well as combination biomarkers, from the two standpoints of predicting MCI conversion to AD and monitoring disease progression at the MCI stage, so as to recommend which biomarkers can reasonably be included in early dementia trials, and how they can best be used.

Authors+Show Affiliations

Department of Geriatric Medicine Tan Tock Seng Hospital, Singapore. Mei_Sian_Chong@ttsh.com.sgNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16869111

Citation

Chong, Mei Sian, et al. "Biomarkers in Preclinical Alzheimer's Disease." Current Opinion in Investigational Drugs (London, England : 2000), vol. 7, no. 7, 2006, pp. 600-7.
Chong MS, Lim WS, Sahadevan S. Biomarkers in preclinical Alzheimer's disease. Curr Opin Investig Drugs. 2006;7(7):600-7.
Chong, M. S., Lim, W. S., & Sahadevan, S. (2006). Biomarkers in preclinical Alzheimer's disease. Current Opinion in Investigational Drugs (London, England : 2000), 7(7), pp. 600-7.
Chong MS, Lim WS, Sahadevan S. Biomarkers in Preclinical Alzheimer's Disease. Curr Opin Investig Drugs. 2006;7(7):600-7. PubMed PMID: 16869111.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biomarkers in preclinical Alzheimer's disease. AU - Chong,Mei Sian, AU - Lim,Wee Shiong, AU - Sahadevan,Suresh, PY - 2006/7/28/pubmed PY - 2006/9/2/medline PY - 2006/7/28/entrez SP - 600 EP - 7 JF - Current opinion in investigational drugs (London, England : 2000) JO - Curr Opin Investig Drugs VL - 7 IS - 7 N2 - With the recent advances in the treatment of Alzheimer's disease (AD) over the last decade, the focus has increasingly shifted to accurate detection of the earliest phase of illness. The intermediate state between normal aging and established AD is commonly known as mild cognitive impairment (MCI). Not all patients with MCI progress to AD and hence there is a need to reliably predict which patients with MCI will progress. The current inability of clinical criteria to accurately identify this at-risk group is fuelling the emerging interest in biomarkers to potentially supplement or replace clinical approaches. Biomarkers have the potential to clearly reflect the progressive deterioration that is present even in the earliest stages of AD--a useful feature for demonstrating the effectiveness or otherwise of a particular dementia drug. This paper will review the evidence regarding the use of cerebrospinal fluid, neuroimaging and blood biomarkers, as well as combination biomarkers, from the two standpoints of predicting MCI conversion to AD and monitoring disease progression at the MCI stage, so as to recommend which biomarkers can reasonably be included in early dementia trials, and how they can best be used. SN - 1472-4472 UR - https://www.unboundmedicine.com/medline/citation/16869111/Biomarkers_in_preclinical_Alzheimer's_disease_ L2 - https://medlineplus.gov/alzheimersdisease.html DB - PRIME DP - Unbound Medicine ER -